In the News: First-Ever AI Parameters Ruling; New Pharma Strategy; and Market Access Restrictions Eased

Beijing IP Court issues first ruling on protecting AI model parameters; Chinese pharma companies are using “NewCo” strategy to expand overseas; and China reduces entry restrictions for select industries.

Credit: Timon/Adobe Stock


Douyin Wins AI Model Unfair Competition Case


On March 31, 2025, the Beijing Intellectual Property Court issued a landmark judgment which, for the first time in China, held that the structure and parameters of AI models “constitute competitive interests protected under the Anti-Unfair Competition Law.”

Douyin, China’s version of TikTok, has a “comic transformation effect” feature on its app on Android.  It is based on a self-developed PIX2PIX model, “which, through a specific neural network structure and parameter configuration, enables users to generate anime-style images that correspond to their real-life appearance when using the Douyin app.” The B612 Kaji app, later developed by Yirui Technology, had a remarkably similar “manga girl effect.” Very similar results arose when photos and videos applied both effects, and the models, when compared, had similarities in multiple respects. Douyin sued, arguing “that its model had been trained with substantial human and computational resources and possessed distinct technical characteristics and strong market competitiveness,”  Xianyang Jiang, a partner at Beijing Hairun Tianrun Law Firm, wrote in an article posted on LinkedIn.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]